Universal reference book for medicines
Product name: DEXONA (DEXONA)

Active substance: dexamethasone, neomycin

Type: The drug with antibacterial and anti-inflammatory action for topical application in ophthalmology and ENT-practice

Manufacturer: CADILA HEALTHCARE (India)
Composition, form of production and packaging
Solution-eye drops and ear
1 ml

dexamethasone sodium phosphate 1 mg

neomycin sulfate 5 mg

Excipients: benzalkonium chloride (preservative), disodium hydrogen phosphate, disodium EDTA, sodium chloride, creatinine, sodium metabisulphite, propylene glycol, water d / u.

5 ml - bottles of dark glass (1) complete with a dropper - packs of cardboard.


The description of the drug was approved by the manufacturer for the 2006 print edition.


Combination drug for topical application.

Neomycin is an antibiotic from the aminoglycoside group, produced by Streptomyces fradiae.
Has a bactericidal effect, disrupting protein synthesis in a microbial cell.Has a wide range of antibacterial action. It is active against many gram-negative and gram-positive microorganisms, including Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus spp., Shigella spp; less active against Pseudomonas aeruginosa and streptococci; is not active against pathogenic fungi, viruses, anaerobic flora. Stability of microorganisms to neomycin develops slowly and is expressed to a small extent.
Dexamethasone - GCS, does not have mineralocorticoid activity.
Has a pronounced anti-inflammatory, antiallergic and desensitizing effect. Dexamethasone actively suppresses inflammatory processes, inhibiting eosinophilic ejection of inflammatory mediators, migration of mast cells and decreasing capillary permeability.
The combination of dexamethasone with neomycin reduces the risk of developing an infectious process.


Data on the pharmacokinetics of the Dexon preparation are not available.


- Acute and chronic bacterial blepharitis;

- Acute and chronic bacterial conjunctivitis;

- Acute and chronic bacterial keratitis (without epithelial damage),

- acute and chronic bacterial iridocyclitis;

- prevention of postoperative inflammation of the anterior part of the eye;

- acute and chronic otitis externa;

- Infectious-allergic diseases of the external ear.


With a mild or moderate infectious disease, the eye is buried in the conjunctival bag 1-2 drops every 4-6 hours. In the case of a serious infectious process, the drug is instilled every hour, as the inflammation decreases, the frequency of instillations of the drug decreases.

When ear infections are instilled in 3-4 drops 2-4 times / day.


When using the drug, there may be adverse reactions that are caused by both SCS and antibiotic, as well as by their combination.

Allergic reactions: often - itching, swelling of the eyelids, redness of the conjunctiva (due to the action of the antibiotic).

From the side of the eye: it is possible to increase intraocular pressure with the risk of subsequent development of glaucoma, as a result of which characteristic lesions of the optic nerve and field of vision, the formation of posterior subcapsular cataract, slowing down the wound healing process (caused by GCS).

In diseases that cause thinning of the cornea or sclera, it is possible to perforate the fibrous membrane with topical application of preparations containing corticosteroids.

After the use of drugs containing glucocorticosteroids in combination with antibiotics, the development of secondary infection can be observed due to the suppression of the protective reaction of the patient's body.
In acute purulent diseases, the eyes of the SCS can mask or strengthen the existing infectious process.
Fungal infection of the cornea tends to occur especially often with prolonged use of GCS.
The appearance of non-healing ulcers on the cornea after prolonged treatment with preparations containing SCS may indicate the development of fungal infestation.

- keratitis caused by the Herpes simplex virus or Varicella zoster (dendritic keratitis);

- chickenpox;

- viral diseases of the cornea and conjunctiva;

- mycobacterial infections of the eyes;

- fungal diseases of the eyes;

- application after uncomplicated removal of a foreign body from the cornea;

- Hypersensitivity to the components of the drug.


In pregnancy, use is only possible in cases where the expected benefit of therapy for the mother exceeds the potential risk to the fetus.

During breastfeeding, discontinue treatment with Dexon drops.


Currently, the effectiveness and safety of the drug in children are not established.


The drug is not intended for injection.

In case of topical application of neomycin simultaneously with the systemic use of aminoglycoside antibiotics, it is necessary to monitor the total concentration of the drug in the blood serum.

When using drugs containing GCS, for more than 10 days should regularly monitor the intraocular pressure.

The patient should be warned that the tip of the pipette should not be touched to any surface to avoid bacterial contamination of the contents of the vial;
During the treatment, contact lenses should not be used.
Special studies to assess the carcinogenic and mutagenic activity of the drug was not conducted.

Use in Pediatrics

Currently, the effectiveness and safety of the drug in children are not established.


Data on the overdose of the drug is not provided.


Data on the medicinal interaction of the drug Dexon are not provided.


The drug is released by prescription.


The drug should be stored in a place protected from light and inaccessible to children at a temperature below 25 ° C.
Do not freeze. Shelf life - 3 years.
After opening the vial, the shelf life is 1 month.

Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!